In October, Gnosis by Lesaffre sponsored the second Global Epigenetics Society International Conference, entitled, “DNA, RNA and Chromatin Epigenetics: Disease and Development,” held in Chicago.
At the conference, the company’s 17-year research partner, Dr Andrea Fuso, presented distinguished research in his lecture, “The Underrated One-Carbon Metabolism and the Pivotal Role of Methylation Reactions in Alzheimer’s Disease.”
Exciting new research findings
In his presentation, Dr Fuso, an expert in neurological and methylation research and Associate Professor in Clinical Biochemistry and Molecular Biology at the Sapienza University of Rome, discussed how B vitamins sustain one-carbon metabolism to make S-Adenosyl-L-methionine (SAMe).
He also explained how insufficient levels of B vitamins impair DNA methylation and boost amyloid/inflammation genes, exacerbating Alzheimer’s-like changes.
Additionally, he discussed how SAMe can restore methylation and how this pathway is a promising target in managing Alzheimer's and protecting brain function.
“Dr Fuso’s presentation was impactful, as his research highlights how maintaining balanced one-carbon metabolism could enhance brain detoxification pathways and protect neuronal integrity, which introduces promising new opportunities for nutraceutical and medical nutrition strategies aimed at supporting cognitive health and longevity,” said Lacey Hall, Global Medical Affairs Director at Gnosis by Lesaffre.
A long-standing collaboration
For more than 20 years, Dr Fuso’s lab has focused its research on epigenetics applied to neurodegenerative diseases, one-carbon metabolism and methylation reactions in relation to the regulation of gene expression.
“Our lab has dedicated the past two decades to unravel the causal association between one-carbon metabolism modulation and DNA methylation, with a translational focus on Alzheimer’s Disease,” Dr Fuso said.
“Gnosis is once again proud to be an integral sponsor of this conference that presents a multifactorial approach to reducing risks of disease development largely generated by impaired DNA methylation and we are exceptionally proud of the work of our esteemed research partner, Dr Fuso,” commented Hall.
“Gnosis remains committed to nurturing relationships between academic researchers and our team that develops innovative nutritional solutions such as Adonat Premium SAMe."
"Further, sponsoring the Epigenetics Society International Conference underscores our dedication to advancing fundamental epigenetic research for clinically relevant applications that promote healthier aging and improved quality of life.”
